First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 6, 2015, Pages

  Xue, Hao ^a   Lu, Zhuang ^a   Tang, Wen Lu ^a   Pang, Lu Wei ^b   Wang, Gan Mi ^a   Wong, Gavin Wk ^c   Wright, James M ^c  

^a FUDAN UNIVERSITY   (China)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CARVEDILOL; CHLORTALIDONE; CILAZAPRIL; CLONIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; ENALAPRIL; HYDROCHLOROTHIAZIDE; IRBESARTAN; LERCANIDIPINE; LISINOPRIL; LOSARTAN; NIFEDIPINE; NISOLDIPINE; NITRENDIPINE; PERINDOPRIL; PRAZOSIN; RAMIPRIL; TELMISARTAN; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VALSARTAN;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR PARAMETERS; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CORRELATIONAL STUDY; DIASTOLIC BLOOD PRESSURE; FOLLOW UP; HEART INFARCTION; HEART RATE; HOSPITALIZATION; HUMAN; HYPERTENSION; META ANALYSIS; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; AGED; CAUSE OF DEATH; CHEMICALLY INDUCED; DRUG EFFECTS; HEART FAILURE; STROKE;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CAUSE OF DEATH; HEART FAILURE; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN-ANGIOTENSIN SYSTEM; STROKE;

EID: 84929443207     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008170.pub2     Document Type: Review

References (121)

1. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288(23):2981-97.
2. Barzilay JI, Davis BR, Cutler JA, Pressel SL, Whelton PK, Basile J, et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Archives of Internal Medicine 2006;166(20):2191-2201.
3. Barzilay JI, Jones CL, Davis BR, Basile JN, Goff DC, Ciocon JO, et al. Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care 2001;24(4):654-8.
4. Black HR, Davis B, Barzilay J, Nwachuku C, Baimbridge C, Marginean H, et al. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care 2008;31(2):353-60.
5. Cushman WC, Ford CE, Einhorn P, Wright JT, Preston RA, Davis BR, Basile JN. Blood pressure control by randomized drug group in ALLHAT. American Journal of Hypertension 2004;17(5):30A.
6. Davis BR, Kostis JB, Simpson LM, Black HR, Cushman WC, Einhorn PT, et al. Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation 2008;118(22):2259-67.
7. Davis BR, Piller LB, Cutler JA, Furberg C, Dunn K, Franklin S, et al. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Circulation 2006;113(18):2201-10.
8. Grimm R, Davis BR, Cutler JA, Piller LB, Margolis K, Barzilay J, et al. Did blood pressure medication withdrawal prior to randomization influence subsequent rates of heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial?. Journal of the American College of Cardiology 2007;49(9 Suppl A):350a.
9. Grimm RH, Davis BR, Piller LB, Cutler JA, Margolis KL, Barzilay J, et al. Heart failure in ALLHAT: did blood pressure medication at study entry influence outcome?. Journal of Clinical Hypertension 2009;11(9):466-74.
10. Haywood LJ, Ford CE, Crow RS, Davis BR, Massie BM, Einhorn PT, et al. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). Journal of the American College of Cardiology 2009;54(22):2023-31.
11. Leenen FHH, Nwachuku CE, Black HR, Cushman WC, Davis BR, Simpson LM, et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 2006;48(3):374-84.
12. Lynch AI, Boerwinkle E, Davis BR, Ford CE, Eckfeldt JH, Leiendecker-Foster C, et al. Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study. Pharmacogenetics and Genomics 2009;19(6):415-21.
13. Lynch AI, Boerwinkle E, Davis BR, Ford CE, Eckfeldt JH, Leiendecker-Foster C, et al. Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension. [Erratum appears in JAMA. 2009 Sep 9;302(10):1057-8]. JAMA 2008;299(3):296-307.
14. Probstfield JL, Cushman WC, Davis BR, Pressel S, Cutler JA, Einhorn P, et al. Mortality and morbidity during and after the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). European Society of Cardiology, ESC Congress; 2010 Aug 28-Sep 1; Stockholm, Sweden. 2010; Vol. 31:321.
15. Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr, Whelton PK, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Archives of Internal Medicine 2005;165(8):936-46.
16. Wright JT Jr, Dunn JK, Cutler JA, Davis BR, Cushman WC, Ford CE, et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA 2005;293(13):1595-608.
17. Wright JT Jr, Harris-Haywood S, Pressel S, Barzilay J, Baimbridge C, Bareis CJ, et al. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Archives of Internal Medicine 2008;168(2):207-17.
18. Zhang X, Lynch AI, Davis BR, Ford CE, Boerwinkle E, Eckfeldt JH, et al. Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study. PLoS ONE [Electronic Resource] 2012;7(3):e34217.
19. Ariff B, Zambanini A, Vamadeva S, Barratt D, Xu Y, Sever P, et al. Candesartan- and atenolol-based treatments induce different patterns of carotid artery and left ventricular remodeling in hypertension. Stroke 2006;37(9):2381-4.
20. Buus NH, Bottcher M, Jorgensen CG, Christensen KL, Thygesen K, Nielsen TT, et al. Myocardial perfusion during long-term angiotensin-converting enzyme inhibition or beta-blockade in patients with essential hypertension. Hypertension 2004;44(4):465-70.
21. Buus NH, Jorgensen CG, Mulvany MJ, Sorensen KE. Large and small artery endothelial function in patients with essential hypertension--effect of ACE inhibition and beta-blockade. Blood Pressure 2007;16(2):106-13.
22. Dahlöf B, Hansson L. The influence of antihypertensive therapy on the structural arteriolar changes in essential hypertension: different effects of enalapril and hydrochlorothiazide. Journal of Internal Medicine 1993;234(3):271-9.
23. Dahlöf B, Zanchetti A, Diez J, Nicholls MG, Yu CM, Barrios V, et al. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. Journal of Hypertension 2002;20(9):1855-64.
24. Dalla Vestra M, Pozza G, Mosca A, Grazioli V, Lapolla A, Fioretto P, et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina). Diabetes Nutrition & Metabolism 2004;17(5):259-66.
25. Derosa G, Cicero AF, Bertone G, Piccinni MN, Fogari E, Ciccarelli L, et al. Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study. Clinical Therapeutics 2004;26(8):1228-36.
26. Derosa G, Cicero AFG, Gaddi A, Mugellini A, Ciccarelli L, Fogari R. Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension. Journal of Cardiovascular Pharmacology 2005;45(6):599-604.
27. Derosa G, Bonaventura A, Bianchi DRL, Fogari E, Angelo AD, Maffioli P. Effects of enalapril/lercanidipine combination on some emerging biomarkers in cardiovascular risk stratification in hypertensive patients. Journal of Clinical Pharmacy and Therapeutics 2014;39:277-85.
28. Devereux RB, Palmieri V, Sharpe N, De Quattro V, Bella JN, de Simone G, et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial. Circulation 2001;104(11):1248-54.
29. Esnault VLM, Brown EA, Apetrei E, Bagon J, Calvo C, DeChatel R, et al. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study. Clinical Therapeutics 2008;30(3):482-98.
30. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23:B54-64.
31. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. New England Journal of Medicine 1998;338(10):645-52.
32. Estacio RO, Schrier RW. Antihypertensive therapy in type 2 diabetes: implications of the appropriate blood pressure control in diabetes (ABCD) trial. American Journal of Cardiology 1998;82(9b):9r-14r.
33. Fogari RZ. Effect of telmisartan on paroxysmal atrial fibrillation recurrence in hypertensive patients with normal or increased left atrial size. Clinical Cardiology 2012;35:359-64.
34. Gerritsen TA, Bak AA, Stolk RP, Jonker JJ, Grobbee DE. Effects of nitrendipine and enalapril on left ventricular mass in patients with non-insulin-dependent diabetes mellitus and hypertension. Journal of Hypertension 1998;16(5):689-96.
35. Gottdiener JS, Reda DJ, Williams DW, Materson BJ, Cushman W, Anderson RJ. Effect of single-drug therapy on reduction of left atrial size in mild to moderate hypertension. Circulation 1998;98(2):140-8.
36. Hajjar I, Hart M, Chen YL, Mack W, Milberg W, Chui H, et al. Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial. Archives of Internal Medicine 2012;172(5):442-4.
37. Hajjar I, Hart M, Chen YL, Mack W, Novak V, Chui C, et al. Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial. Journal of the American Geriatrics Society 2013;61(2):194-201.
38. Hauf-Zachariou U, Widmann L, Zülsdorf B, Hennig M, Lang PD. A double-blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemia. European Journal of Clinical Pharmacology 1993;45(2):95-100.
39. Hayoz D, Zappe DH, Meyer MA, Baek I, Kandra A, Joly MP, et al. Changes in aortic pulse wave velocity in hypertensive postmenopausal women: comparison between a calcium channel blocker vs angiotensin receptor blocker regimen. Journal of Clinical Hypertension 2012;14(11):773-8.
40. Himmelmann A, Hansson L, Hansson BG, Hedstrand H, Skogström K, Ohrvik J, et al. Long-term renal preservation in essential hypertension. Angiotensin converting enzyme inhibition is superior to beta-blockade. American Journal of Hypertension 1996;9(9):850-3.
41. Hughes AD, Stanton AV, Jabbar AS, Chapman N, Martinez-Perez ME, Thom SAMcG. Effect of antihypertensive treatment on retinal microvascular changes in hypertension. Journal of Hypertension 2008;26(8):1703-7.
42. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Annals of Internal Medicine 2003;138(7):542-9.
43. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New England Journal of Medicine 2001;345(12):851-60.
44. Dahlöf B, Devereux R, de Faire U, Fyhrquist F, Hedner T, Ibsen H, et al. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. American Journal of Hypertension 1997;10(7 Pt 1):705-13.
45. Dahlöf B, Devereux RB, Julius S, Kjeldsen SE, Beevers G, de Faire U, et al. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. Hypertension 1998;32(6):989-97.
46. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359(9311):995-1003.
47. Devereux RB, Dahlöf B, Kjeldsen SE, Julius S, Aurup P, Beevers G, et al. Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial. Annals of Internal Medicine 2003;139(3):169-77.
48. Fossum E, Moan A, Kjeldsen SE, Devereux RB, Julius S, Snapinn SM, et al. The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study. Journal of the American College of Cardiology 2005;46(5):770-5.
49. Franklin SS, Wachtell K, Papademetriou V, Olsen MH, Devereux RB, Fyhrquist F, et al. Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy. Hypertension 2005;46(3):492-9.
50. Gerdts E, Franklin S, Rieck A, Papademetriou V, Wachtell K, Nieminen M, et al. Pulse pressure, left ventricular function and cardiovascular events during antihypertensive treatment (the LIFE study). Blood Pressure 2009;18(4):180-6.
51. Julius S, Alderman MH, Beevers G, Dahlöf B, Devereux RB, Douglas JG, et al. Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study. Journal of the American College of Cardiology 2004;43(6):1047-55.
52. Kizer JR, Dahlof B, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. Hypertension 2005;45(1):46-52.
53. Kjeldsen SE, Lyle PA, Kizer JR, Dahlof B, Devereux RB, Julius S, et al. The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study. Journal of Clinical Hypertension 2005;7(3):152-8.
54. Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359(9311):1004-10.
55. Okin PM. Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients. Journal of Electrocardiology 2009;42(6):584-8.
56. Okin PM, Bang CN, Wachtell K, Hille DA, Kjeldsen SE, Dahlof B, et al. Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy. Circulation: Arrhythmia and Electrophysiology 2013;6(2):243-51.
57. Okin PM, Hille DA, Kjeldsen SE, Lindholm LH, Edelman JM, Dahlof B, et al. Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients. American Journal of Hypertension 2010;23(7):786-93.
58. Olsen MH, Wachtell K, Beevers G, Dahlof B, de Simone G, Devereux RB, et al. Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study. Journal of Hypertension 2009;27(3):567-74.
59. Os I, Franco V, Kjeldsen SE, Manhem K, Devereux RB, Gerdts E, et al. Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 2008;51(4):1103-8.
60. Malmqvist K, Kahan T, Edner M, Bergfeldt L. Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA). American Journal of Cardiology 2002;90(10):1107-12.
61. Malmqvist K, Öhman KP, Lind L, Nyström F, Kahan T. Long-term effects of irbesartan and atenolol on the renin-angiotensin-aldosterone system in human primary hypertension: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). Journal of Cardiovascular Pharmacology 2003;42:719-26.
62. Mortsell D, Malmqvist K, Held C, Kahan T. Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study. Journal of Internal Medicine 2007;261(5):472-9.
63. Ostman J, Asplund K, Bystedt T, Dahlöf B, Jern S, Kjellström T, et al. Comparison of effects of quinapril and metoprolol on glycaemic control, serum lipids, blood pressure, albuminuria and quality of life in non-insulin-dependent diabetes mellitus patients with hypertension. Swedish Quinapril Group. Journal of Internal Medicine 1998;244(2):95-107.
64. Parrinello G, Paterna S, Torres D, Di Pasquale P, Mezzero M, La Rocca G, et al. One-year renal and cardiac effects of bisoprolol versus losartan in recently diagnosed hypertensive patients: a randomized, double-blind study. Clinical Drug Investigation 2009;29(9):591-600.
65. Pedersen EB, Bech JN, Nielsen CB, Kornerup HJ, Hansen HE, Spencer ES, et al. A comparison of the effect of ramipril, felodipine and placebo on glomerular filtration rate, albuminuria, blood pressure and vasoactive hormones in chronic glomerulonephritis. A randomized, prospective, double-blind, placebo-controlled study over two years. Scandinavian Journal of Clinical & Laboratory Investigation 1997;57(8):673-81.
66. Petersen LJ, Petersen JR, Talleruphuus U, Moller ML, Ladefoged SD, Mehlsen J. A randomized and double-blind comparison of isradipine and spirapril as monotherapy and in combination on the decline in renal function in patients with chronic renal failure and hypertension. Clinical Nephrology 2001;55:375-83.
67. Roman MJ, Alderman MH, Pickering TG, Pini R, Keating JO, Sealey JE, et al. Differential effects of angiotensin converting enzyme inhibition and diuretic therapy on reductions in ambulatory blood pressure, left ventricular mass, and vascular hypertrophy. American Journal of Hypertension 1998;11(4 Pt 1):387-96.
68. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al. Preventing microalbuminuria in type 2 diabetes. New England Journal of Medicine 2004;351(19):1941-51.
69. Schiffrin EL, Deng LY, Larochelle P. Effects of a beta-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension. Hypertension 1994;23(1):83-91.
70. Schmieder RE, Philipp T, Guerediaga J, Gorostidi M, Smith B, Weissbach N, et al. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation 2009;119(3):417-25.
71. Schneider MP, Klingbeil AU, Delles C, Ludwig M, Kolloch RE, Krekler M, et al. Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the CardioVascular Irbesartan Project. Hypertension 2004;44(1):61-6.
72. Schram MT, van Ittersum FJ, Spoelstra-de Man A, van Dijk RAJM, Schalkwijk CG, Ijzerman RG, et al. Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trial. Journal of Human Hypertension 2005;19(6):429-37.
73. Seedat YK, Randeree IG. Antihypertensive effect and tolerability of perindopril in Indian hypertensive and type 2 diabetic patients: 1-year randomised, double-blind, parallel study vs atenolol. Clinical Drug Investigation 1998;16(3):229-240.
74. Sørensen VB, Rossing P, Tarnow L, Parving H, Nørgaard T, Kastrup J. Effects of nisoldipine and lisinopril on microvascular dysfunction in hypertensive type I diabetes patients with nephropathy. Clinical Science 1998;95(6):709-17.
75. Tarnow L, Sato A, Ali S, Rossing P, Nielsen FS, Parving HH. Effects of nisoldipine and lisinopril on left ventricular mass and function in diabetic nephropathy. Diabetes Care 1999;22(3):491-4.
76. Tedesco MA, Ratti G, Mennella S, Manzo G, Grieco M, Rainone AC, et al. Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. American Journal of Hypertension 1999;12(11 Pt 1):1130-4.
77. Terpstra WF, May JF, Smit AJ, Graeff PA, Meyboom-de Jong B, Crijns HJGM. Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). Journal of Hypertension 2004;22(7):1309-16.
78. Neaton JD, Grimm RH Jr, Prineas RJ, Stamler J, Grandits GA, Elmer PJ, et al. Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA 1993;270(6):713-24.
79. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363(9426):2022-31.
80. Julius S, Weber MA, Kjeldsen SE, McInnes GT, Zanchetti A, Brunner HR, et al. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension 2006;48(3):385-91.
81. Mann J, Julius S. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Pressure 1998;7(3):176-83.
82. Sandset E, Krarup LH, Berge E, Kjeldsen SE, Julius S, Holzhauer B. Predictors of stroke recurrence in high-risk, hypertensive patients. Journal of Hypertension 2010;28(A):E33.
83. Zanchetti A, Julius S, Kjeldsen S, McInnes GT, Hua T, Weber M, et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. Journal of Hypertension 2006;24(11):2163-8.
84. Zeltner R, Poliak R, Stiasny B, Schmieder RE, Schulze BD. Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation 2008;23(2):573-9.
85. Wright JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. JAMA 2002;288(19):2421-31.
86. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. New England Journal of Medicine 1993;328(13):914-21.
87. Okin PM, Kjeldsen SE, Lindholm LH, Dahlof B, Devereux RB. The relationship of electrocardiographic left ventricular hypertrophy to decreased serum potassium. Blood Pressure 2012;21:146-52.
88. Preston RA, Materson BJ, Reda DJ, Williams DW, Hamburger RJ, Cushman WC, et al. Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. JAMA 1998;280(13):1168-72.
89. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23(suppl 2):B54-64.
90. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2013;36(suppl 1):S11-66.
91. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, Hill S, Jaeschke R, Leng G, Liberati A, Magrini N, Mason J, Middleton P, Mrukowicz J, O'Connell D, Oxman AD, Phillips B, Schünemann HJ, Edejer T, Varonen H, Vist GE, Williams JW Jr, Zaza S, GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004;328(7454):1490-4.
92. Aurell M, Bjorck S. Determinants of progressive renal disease in diabetes mellitus. Kidney Int Suppl 1992;41(suppl 36):S38-42.
93. Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A, CAPPP Study Group. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project (CAPPP). Diabetes Care 2001;24:2091-6.
94. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005;366(9502):2026-33.
95. Chen N, Zhou M, Yang M, Guo J, Zhu C, Yang J, et al. Calcium channel blockers versus other classes of drugs for hypertension. Cochrane Database of Systematic Reviews 2010, Issue 8. [DOI: 10.1002/14651858.CD003654.pub4]
96. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada - Treatment of Hypertension. Canadian Journal of Diabetes 2013;37(Suppl 1):S117-8.
97. DeStefano F, Ford ES, Newman J, Stevenson JM, Wetterhall SF, Anda RF, et al. Risk factors for coronary heart disease mortality among persons with diabetes. Annals of Epidemiology 1993;3:27-34.
98. Duprez, D. Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review. Journal of Hypertension 2006;24:983-91.
99. Dzau VJ. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001;37:1047-52.
100. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension 2013;31(7):1281-357.
101. Geiss LS, Rolka DB, Engelgau MM. Elevated blood pressure among U.S. adults with diabetes, 1988-1994. American Journal of Preventive Medicine 2002;22:42-8.
102. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
103. Heart Outcomes Prevention Evaluation (HOPE) Study investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Lancet 2000;355:253-9.
104. Inzucchi SE, Sherwin RS. The prevention of type 2 diabetes mellitus. Endocrinology and Metabolism Clinics of North America 2005;34(1):199-219.
105. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311(5):507-20.
106. Kasiske BL, Kalil RS, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta regression analysis. Annals of Internal Medicine 1993;118(2):129-38.
107. Kocks MJ, de Zeeuw D, Navis GJ. Optimal blood pressure control and antihypertensive regimens in hypertensive renal disease. Current Opinion in Nephrology and Hypertension 2002;11:135-40.
108. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
109. MARVAL Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. Circulation 2002;106:672-8.
110. Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Furberg CD. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care 2000;23:888-92.
111. PROGRESS Collaborative Study Group. Randomised trial of perindopril based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41.
112. Ravine D, Gibson RN, Walker RG, Sheffield LJ, Kincaid-Smith P, Danks DM. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet 1994;343(8901):824-7.
113. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New England Journal of Medicine 2001;345:861-9.
114. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
115. Saha SA, Molnar J, Arora RR. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials. Diabetes Obesity and Metabolism 2008;10(1):41-52.
116. Siebenhofer A, Plank J, Horvath K, Berghold A, Sutton AJ, Sommer R, et al. Angiotensin receptor blockers as anti-hypertensive treatment for patients with diabetes mellitus: meta-analysis of controlled double-blind randomized trials. Diabetic Medicine 2004;21(1):18-25.
117. Strippoli GFM, Craig ME, Craig JC. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD004136.pub2]
118. Strippoli GFM, Bonifati C, Craig ME, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: 10.1002/14651858.CD006257]
119. Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Mbewu A, Opie LH. Beta-blockers for hypertension. Cochrane Database of Systematic Reviews 2012, Issue 11. [DOI: 10.1002/14651858.CD002003.pub4]
120. Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD001841.pub2]
121. Wu HY, Huang JW, Lin HJ, Liao WC, Peng YS, Hung KY, et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis. BMJ 2013;347(7933):f6008. [DOI: 10.1136/bmj.f6008]